Overview Dividends

(HAE) Haemonetics - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4050241003

Plasma Collection, Hemostasis Analyzer, Blood Recovery, Vascular Closure

Health Care Supplies
Market Cap in USD: 3,853m

IPO / Inception: 1991-05-09
Return 12m vs S&P 500: -10.7%

EPS (Earnings per Share)

EPS CAGR: 11.65%
EPS Trend: 85.8%

Last SUE: 4.00
Qual. Beats: 1

Revenue

Rev. CAGR: 6.36%
Rev. Trend: 83.3%

Last SUE: 1.98
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	34.2%
Value at Risk 5%th	49.7%
Relative Tail Risk	-11.64%

Reward TTM
Sharpe Ratio	0.25
Alpha	-8.50
CAGR/Max DD	0.06

Character TTM
Hurst Exponent	0.408
Beta	0.636
Beta Downside	0.141

Drawdowns 3y
Max DD	51.04%
Mean DD	18.01%
Median DD	14.57%

Description: HAE Haemonetics November 08, 2025

Haemonetics (NYSE:HAE) is a medical-technology firm that sells a diversified portfolio of hospital-focused solutions. Its core segments include automated plasma-collection systems (NexSys PCS/PCS2) with associated disposables, donor-management software (NexLynk DMS, Donor360), and a suite of hemostasis and blood-conservation products such as TEG/HAS analyzers, Cell Saver Elite+, and VASCADE vascular-closure devices. The company also markets specialty interventional tools-including the SavvyWire 3-in-1 guidewire for TAVR and the OptoWire pressure guidewire-plus fiber-optic sensor technologies for broader medical and industrial use.

In fiscal 2023 Haemonetics reported revenue of roughly $1.1 billion, up about 6 % year-over-year, driven primarily by higher plasma-collection volumes and growing adoption of its TEG hemostasis platform in critical-care settings. Operating margin hovered near 14 %, supported by a disciplined cost-structure and a cash-flow conversion rate of ~85 %, leaving the balance sheet with >$300 million of unrestricted cash. Key macro drivers for the business are the aging U.S. and global populations, which boost demand for plasma-derived therapeutics, and the expanding use of point-of-care coagulation testing in surgical and trauma centers-both trends that historically exhibit double-digit annual growth rates in the health-care supplies sub-industry.

For a deeper quantitative assessment, the ValueRay platform provides a granular breakdown of HAE’s valuation metrics and scenario analyses.

Piotroski VR‑10 (Strict, 0-10) 8.5

Net Income (168.2m TTM) > 0 and > 6% of Revenue (6% = 79.7m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 8.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 26.46% (prev 50.10%; Δ -23.64pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 289.0m > Net Income 168.2m (YES >=105%, WARN >=100%)

Net Debt (928.3m) to EBITDA (375.1m) ratio: 2.47 <= 3.0 (WARN <= 3.5)

Current Ratio 1.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (47.7m) change vs 12m ago -6.98% (target <= -2.0% for YES)

Gross Margin 58.71% (prev 54.68%; Δ 4.03pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 53.46% (prev 53.91%; Δ -0.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 12.43 (EBITDA TTM 375.1m / Interest Expense TTM 21.0m) >= 6 (WARN >= 3)

Altman Z'' 2.29

(A) 0.14 = (Total Current Assets 899.7m - Total Current Liabilities 548.3m) / Total Assets 2.44b

(B) 0.14 = Retained Earnings (Balance) 336.3m / Total Assets 2.44b

(D) 0.19 = Book Value of Equity 296.3m / Total Liabilities 1.59b

Total Rating: 2.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.50

1. Piotroski 8.50pt

2. FCF Yield 5.36%

3. FCF Margin 19.29%

4. Debt/Equity 1.44

5. Debt/Ebitda 2.47

6. ROIC - WACC (= 2.97)%

7. RoE 19.45%

8. Rev. Trend 83.32%

9. EPS Trend 85.79%

What is the price of HAE shares?

As of January 07, 2026, the stock is trading at USD 82.77 with a total of 515,401 shares traded.
Over the past week, the price has changed by +2.21%, over one month by -0.53%, over three months by +67.04% and over the past year by +5.02%.

Is HAE a buy, sell or hold?

Haemonetics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy HAE.

Strong Buy: 3
Buy: 5
Hold: 1
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HAE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	90.2	9%
Analysts Target Price	90.2	9%
ValueRay Target Price	82.9	0.2%

HAE Fundamental Data Overview January 04, 2026

Market Cap USD = 3.85b (3.85b USD * 1.0 USD.USD)
P/E Trailing = 23.386
P/E Forward = 14.7059
P/S = 2.9018
P/B = 4.4182
P/EG = 1.2255
Beta = 0.3
Revenue TTM = 1.33b USD
EBIT TTM = 260.9m USD
EBITDA TTM = 375.1m USD
Long Term Debt = 920.4m USD (from longTermDebt, last quarter)
Short Term Debt = 304.3m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 928.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.78b USD (3.85b + Debt 1.22b - CCE 296.4m)
Interest Coverage Ratio = 12.43 (Ebit TTM 260.9m / Interest Expense TTM 21.0m)
FCF Yield = 5.36% (FCF TTM 256.1m / Enterprise Value 4.78b)
FCF Margin = 19.29% (FCF TTM 256.1m / Revenue TTM 1.33b)
Net Margin = 12.67% (Net Income TTM 168.2m / Revenue TTM 1.33b)
Gross Margin = 58.71% ((Revenue TTM 1.33b - Cost of Revenue TTM 548.3m) / Revenue TTM)
Gross Margin QoQ = 59.50% (prev 59.70%)
Tobins Q-Ratio = 1.96 (Enterprise Value 4.78b / Total Assets 2.44b)
Interest Expense / Debt = 0.59% (Interest Expense 7.21m / Debt 1.22b)
Taxrate = 24.57% (12.6m / 51.3m)
NOPAT = 196.8m (EBIT 260.9m * (1 - 24.57%))
Current Ratio = 1.64 (Total Current Assets 899.7m / Total Current Liabilities 548.3m)
Debt / Equity = 1.44 (Debt 1.22b / totalStockholderEquity, last quarter 849.2m)
Debt / EBITDA = 2.47 (Net Debt 928.3m / EBITDA 375.1m)
Debt / FCF = 3.63 (Net Debt 928.3m / FCF TTM 256.1m)
Total Stockholder Equity = 864.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.89% (Net Income 168.2m / Total Assets 2.44b)
RoE = 19.45% (Net Income TTM 168.2m / Total Stockholder Equity 864.8m)
RoCE = 14.61% (EBIT 260.9m / Capital Employed (Equity 864.8m + L.T.Debt 920.4m))
RoIC = 9.42% (NOPAT 196.8m / Invested Capital 2.09b)
WACC = 6.45% (E(3.85b)/V(5.08b) * Re(8.36%) + D(1.22b)/V(5.08b) * Rd(0.59%) * (1-Tc(0.25)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 80.42% ; FCFE base≈171.9m ; Y1≈212.0m ; Y5≈361.7m
Fair Price DCF = 123.6 (DCF Value 5.79b / Shares Outstanding 46.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 85.79 | EPS CAGR: 11.65% | SUE: 4.0 | # QB: 1
Revenue Correlation: 83.32 | Revenue CAGR: 6.36% | SUE: 1.98 | # QB: 2
EPS current Year (2026-03-31): EPS=4.91 | Chg30d=+0.000 | Revisions Net=+11 | Growth EPS=+7.5% | Growth Revenue=-3.1%
EPS next Year (2027-03-31): EPS=5.47 | Chg30d=-0.020 | Revisions Net=-2 | Growth EPS=+11.3% | Growth Revenue=+6.0%

Additional Sources for HAE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle